The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1642
ISSUE1642
January 24, 2022
Bupivacaine/Meloxicam (Zynrelef) for Postsurgical Pain
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Bupivacaine/Meloxicam (Zynrelef) for Postsurgical Pain
January 24, 2022 (Issue: 1642)
The FDA has approved a fixed-dose combination
of the amide local anesthetic bupivacaine and
the nonsteroidal anti-inflammatory drug (NSAID)
meloxicam as an extended-release (ER) solution
(Zynrelef – Heron) for single-dose,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.